Beam Therapeutics Inc. (BEAM) Reports Updated Data From BEACON Phase 1/2 trial Of Ristoglogene [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
TheFly reported on December 2, 2025, that Beam Therapeutics Inc. (NASDAQ:BEAM) has released revised safety and effectiveness information from its BEACON Phase 1/2 clinical trial evaluating ristoglogene autogetemcel (previously BEAM-101). It is an investigational genetically engineered ex vivo base editing cell therapy for sickle cell disease patients suffering from severe vaso-occlusive crises. The information was shown during the 67th Annual Meeting and Exposition of the American Society of Hematology in Orlando. A total of 31 adults and adolescents were treated with risto-cel and were included in the updated results. The company reported a decline of hemoglobin S to less than 40%, a remission of anemia that lasted up to 20 months, and a mean fetal hemoglobin induction of more than 60%. A median of one cell collection cycle was needed for each patient. After treatment, rapid neutrophil and platelet engraftment were seen. According to the firm, busulfan conditioning, autologous hem
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics: Pivoting From Platform To Execution Stage [Seeking Alpha]Seeking Alpha
- Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029 [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Advances Genetic, Hematology Pipeline, Extends Cash Runway to 2029; Shares Rise [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial TransitionGlobeNewswire
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 1/15/26 - Form 144
- 1/12/26 - Form 8-K
- 1/5/26 - Form 4
- BEAM's page on the SEC website